Random urine testing: As an intervention for drug addiction

Psychiatric Annals

Volumn 34, Issue 10, 2004, Pages 781-784

  Jacobs, William S ^a   Repetto, Martin ^a   Vinson, Sarah ^b   Pomm, Raymond ^c   Gold, Mark S ^b,d  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Phys's Resource Recovery Network   (United States)

^d Neurosci A ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CANNABIS; CREATININE;

ABSTINENCE; BLOOD SAMPLING; DEMOGRAPHY; DIAGNOSTIC TEST; DRUG DEPENDENCE; FEASIBILITY STUDY; HUMAN; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MEDICAL RESEARCH; MENTAL HEALTH; PSYCHIATRY; PUBLISHING; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZATION; REVIEW; UNITED STATES; URINALYSIS;

EID: 12344307064     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20041001-18     Document Type: Review

References (31)

1. Preston KL, Silverman K, Schuster CR, Cone EJ. Comparison of self-reported drug use with quantitative and qualitative urinalysis for assessment of drug use in treatment studies. NIDA Res Monogr. 1997;167:130-145.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders [text revision]. 4th ed. Washington, DC: American Psychiatric Publishing; 2000.
3. Frost-Pineda K, Gold MS, Pomm R, Jacobs WS, Repetto M. Randomized urine testing: a safe and effective intervention for drug addiction. Presented at: American College of Clinical Pharmacology 32nd Annual Meeting; September 21, 2003; Palm Harbor, FL.
4. O'Brien CP, McLellan AT. Myths about the treatment of addiction. Lancet. 1996;347 (8996):237-240.
5. Moore KA, Levine B, Fowler DR. Prediction of impairment from urine benzoylecgonine concentrations. J Anal Toxicol. 2003;27 (6):383-384.
6. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Mandatory Guidelines for Federal Workplace Drug Testing Programs. September 1, 1994. Available at: http://workplace.samhsa.gov/ ResourceCenter/r362.htm. Accessed August 27, 2004.
7. Meeker JE, Mount AM, Ross W. Detection of drug abuse by health professionals. J Healthc Prot Manage. 2003;19(1):73-81.
8. Chou SL, Yang MH, Ling YC, Giang YS. Gas chromatography-isotope dilution mass spectrometry preceded by liquid-liquid extraction and chemical derivatization for the determination of ketamine and norketamine in urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;799(1):37-50.
9. Rubingh C. Urine opioid screens may be misleading. J Pain Palliat Care Pharmacother. 2002;16(2):103-104.
10. Von Seggern RL, Fitzgerald CP, Adelman LC, Adelman JU. Laboratory monitoring of Oxy-Contin (oxycodone): clinical pitfalls. Headache. 2004;44(1):44-47.
11. Nordgren HK, Beck O. Direct screening of urine for MDMA and MDA by liquid chromatography-tandem mass spectrometry. J Anal Toxicol. 2003;27(1):15-19.
12. Nordgren HK, Beck O. Multicomponent screening for drugs of abuse: direct analysis of urine by LC-MS-MS. Ther Drug Monit. 2004;26(1):90-97.
13. Dams R, Murphy CM, Lambert WE, Huestis MA. Urine drug testing for opioids, cocaine, and metabolites by direct injection liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2003; 17(14):1665-1670.
14. Fraser AD, Zamecnik J. Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators. Ther Drug Monit. 2003;25(6):723-727.
15. Luzzi VI, Saunders AN, Koenig JW, et al. Analytic performance of immunoassays for drugs of abuse below established cutoff values. Clin Chem. 2004;50(4):717-722. Epub 2004 Feb 05.
16. De Cock KJ, Delbeke FT, De Boer D, Van Eenoo P, Roels K. Quantitation of 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid with GC-MS in urine collected for doping analysis. J Anal Toxicol. 2003;27(2):106-109.
17. Dasgupta A. Urinary adulterants and drugs-of-abuse testing. MLO Med Lab Obs. 2003;35(2):26-28, 30-31.
18. Peace MR, Tarnai LD. Performance evaluation of three on-site adulterant detection devices for urine specimens. J Anal Toxicol. 2002;26(7):464-470.
19. Valtier S, Cody JT. A procedure for the detection of Stealth adulterant in urine samples. Clin Lab Sci. 2002;15(2):111-115.
20. Willette RE. Drug testing in the workplace. In: Graham A, Schultz T, eds. Principles of Addiction Medicine. 3rd ed. Chevy Chase. MD: American Society of Addiction Medicine; 1999.
21. Edgell K, Caplan YH, Glass LR, Cook JD. The defined HHS/DOT substituted urine criteria validated through a controlled hydration study. J Anal Toxicol. 2002;26(7):419-423.
22. Josefson D. Arkansas bans selling of clean urine to beat drug testing. BMJ. 2003;326(7384):300.
23. Huestis MA, Cone EJ. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol. 1998;22(6):445-454.
24. Fraser AD, Worth D. Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: a cannabinoid-to-creatinine ratio study. Ther Drug Monit. 2002;24(6):746-450.
25. Fraser AD, Worth D. Urinary excretion profiles of 11-nor-9-carboxy- Delta9-tetrahydrocannabinol: a Delta9-THC-COOH to creatinine ratio study #2. Forensic Sci Int. 2003 Apr 23;133(1-2):26-31.
26. Fraser AD, Worth D. Urinary excretion profiles of 11-nor-9-carboxy- Delta9-tetrahydrocannabinol. Study III. A Delta9-THC-COOH to creatinine ratio study. Forensic Sci Int. 2003;137(2-3):196-202.
27. Cone EJ, Sampson-Cone AH, Darwin WD, Huestis MA, Oyler JM. Urine testing for cocaine abuse: metabolic and excretion patterns following different routes of administration and methods for detection of false-negative results. J Anal Toxicol. 2003;27(7): 386-401.
28. Bruns AD, Zieske LA, Jacobs AJ. Analysis of the cocaine metabolite in the urine of patients and physicians during clinical use. Otolaryngol Head Neck Surg. 1994;111(6):722-726.
29. Jacobs WS, Hall JD, Pomm R, et al. Prognostic factors for physician addiction outcomes at five years. Presented at: American Society of Addition Medicine Annual Medical-Scientific Meeting; April 24, 2004; Washington, DC.
30. Crosby RD, Carlson GA, Specker SM, Simulation of drug use and urine screening patterns. J Addict Dis. 2003;22(3):89-98:
31. Peat MA. Financial viability of screening for drugs of abuse. Clin Chem. 1995;41(5):805-808.